Ketoconazole Topical and Warfarin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Warfarin
Ketoconazole Topical
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased warfarin exposure, an increased INR and an increased risk of bleeding
Interaction Deep Dive
Coadministration of CYP3A4 inhibitors, such as ketoconazole, with warfarin (CYP3A4 substrate) may increase warfarin exposure and may increase INR. Consider the CYP3A4 inhibition potential when starting, stopping, or changing dose of concomitant medications4. Concomitant use with warfarin may result in increased risk of bleeding. In a nested case-control study of continuous warfarin users aged 65 years or older, there was 4.5-fold increase in risk of bleeding requiring hospitalization with exposure to azole antifungals, including ketoconazole 5. If ketoconazole therapy is required in a patient taking warfarin, more frequent monitoring of INR is recommended, especially when ketoconazole is initiated and discontinued 6. Reduce warfarin dosage as deemed necessary 2.
Why it happens (mechanism)
Disruption of vitamin K synthesis; inhibition of CYP3A4-mediated metabolism of warfarin
Literature reports
4 reports — tap to read
a) Initiation of antibiotics in patients on continuous warfarin therapy resulted in a significantly increased risk of serious bleeding requiring hospitalization according to a nested case-control study of United States Medicare part D beneficiaries aged 65 years and older (n=38,762). Patients on warfarin who received any antibiotic were twice as likely to be hospitalized for bleeding compared with matched controls on warfarin who were not exposed to antibiotics (adjusted odds ratio (aOR), 2.01; 95% CI, 1.62 to 2.5). Additionally, continuous-warfarin users were twice as likely to have a bleeding event that required hospitalization within 60 days of antibiotic exposure compared with non-exposure. Antibiotic exposure greater than 60 days from the index bleed was not significantly associated with increased risk of bleeding. Specific antibiotics with the highest bleeding risk were azole antifungals (aOR, 4.57; 95% CI, 1.9 to 11.03), followed by cotrimoxazole (aOR, 2.7; 95% CI, 1.46 to 5.05), cephalosporins (aOR, 2.45; 95% CI, 1.52 to 3.95), penicillins (aOR, 1.92; 95% CI, 1.21 to 2.07), macrolides (aOR, 1.86; 95% CI, 1.08 to 3.21), and quinolones (aOR, 1.69; 95% CI, 1.09 to 2.62) 5.
b) Ketoconazole has been reported to potentiate the anticoagulant effect of warfarin in a single case study. A 75-year-old woman stabilized on warfarin for 3 years was administered ketoconazole 200 mg twice daily for a chronic vaginal thrush infection. Three weeks after treatment, the patient was noted to have spontaneous bleeding and a decrease in her coagulation control. The patient had received no other drugs and had normal liver function tests and CBC. Treatment consisted of stopping ketoconazole therapy and reducing the warfarin dosage. Warfarin control was reestablished at her previous dosage level over the next 3 weeks 3.
c) It is recommended that patients treated with warfarin may need a reduction in dosage by approximately one-third with concurrent administration of ketoconazole 3.
d) No hypoprothrombinemic interaction was found in 2 volunteers who received 200 mg ketoconazole plus 7.5 mg to 15 mg warfarin for 3 weeks 1.
Common questions
Can I take Ketoconazole Topical and Warfarin together?
Increased warfarin exposure, an increased INR and an increased risk of bleeding Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ketoconazole Topical and Warfarin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "delayed". Effects tend to build up gradually over days to weeks.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Ketoconazole Topical or Warfarin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (6)
- Brass C, Galgiani JN, Blaschke TF, et al: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 1982; 21:151-158. PubMed
- Product Information: Ketoconazole oral tablet, ketoconazole oral tablet. Taro Pharmaceuticals U.S.A. Inc. (per DailyMed), Hawthorne, NY, 2024. DailyMed
- Smith AG: Potentiation of oral anticoagulants by ketoconazole. Br Med J 1984; 288:188-189. PubMed
- Product Information: WARFARIN SODIUM oral tablets, warfarin sodium oral tablets. Teva Pharmaceuticals (per Dailymed), Parsippany, NJ, 2023. DailyMed
- Baillargeon J, Holmes HM, Lin YL, et al: Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012; 125(2):183-189. PubMed
- Product Information: COUMADIN(R) oral tablets, intravenous injection powder lyophilized for solution, warfarin sodium oral tablets, intravenous injection powder lyophilized for solution. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2011. DailyMed
Keep reading about Warfarin
Keep reading about Ketoconazole Topical
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist